Kezar Life Sciences (KZR)
(Delayed Data from NSDQ)
$4.10 USD
+0.03 (0.74%)
Updated Aug 6, 2025 04:00 PM ET
After-Market: $4.10 0.00 (0.00%) 7:58 PM ET
3-Hold of 5 3
F Value F Growth A Momentum F VGM
Fundamental Charts
About Dividend Yield (TTM)
Kezar Life Sciences, Inc.'s dividend yield currently sits at 0%, which is in-line with the Medical - Biomedical and Genetics industry's yield of 0.00%.
The company's trailing twelve month (TTM) Dividend Yield calculates the indicated annual dividend divided by the stock price. This value is always expressed as a percentage. This is the return on investment that is specifically attributed to the expected dividends that are paid out over a year. Note: investors should not base their investments on the size of the dividend yield alone. Seek attractive dividend yields, but only on top rated stocks with a solid payment history.
KZR 4.10 +0.03(0.74%)
Will KZR be a Portfolio Killer in August?
Zacks Investment Research is releasing its prediction for KZR based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for KZR
Kezar Life Sciences (KZR) Upgraded to Buy: What Does It Mean for the Stock?
VistaGen Therapeutics, Inc. (VTGN) Reports Q2 Loss, Misses Revenue Estimates
KZR: What are Zacks experts saying now?
Zacks Private Portfolio Services
Anika Therapeutics (ANIK) Reports Q3 Loss, Lags Revenue Estimates
What Makes Kezar Life Sciences (KZR) a New Buy Stock
Other News for KZR
KZR: Kezar Life Sciences Maintains Neutral Rating by HC Wainwright & Co. | KZR Stock News
Kezar Life Sciences Announces FDA Has Lifted Partial Clinical Hold on PORTOLA Phase 2a Trial ...
Kezar Life Sciences (KZR) Seeks to Lift Hold on Zetomipzomib Trials | KZR Stock News
Kezar Life Sciences lifts partial clinical hold on PORTOLA Phase 2a trial
Kalamazoo Resources Updates Registered Office Address